- Details
- Charles Ryan is joined by the leadership of the Prostate Cancer Clinical Trials Consortium, a group that has developed innumerable trials and therapies for advanced prostate cancer. The Prostate Cancer Clinical Trials Consortium (PCCTC) was initiated in 2005 by the Prostate Cancer Foundation (PCF) and the U.S. Department of Defense (DOD) Prostate Cancer Research Program (PCRP) in response to criti...
|
- Details
- Javid Moslehi joins Alicia Morgans in a conversation on the cardiovascular health of cancer patients. Javid Moslehi's laboratory focuses on mechanistic understanding of cardiovascular toxicities that result from novel “targeted” cancer therapies. In this conversation, they discuss the cardiovascular toxicities associated with androgen deprivation therapy (ADT) and the physiologic mechanisms and ma...
|
- Details
- Sam Denmeade and Michael Schweizer join Charles Ryan at the 2019 Prostate Cancer Foundation Retreat (PCF 2019) to discuss testosterone replacement in advanced prostate cancer. The three discuss the impact of testosterone on prostate cancer cells, recent clinical trials involving testosterone replacement and the risks and benefits of adding this therapy to one’s treatment plan for prostate cancer p...
|
- Details
- Justin Drake, University of Minnesota, discusses the latest and ongoing research associated with the correlation between RET gene expression and neuroendocrine prostate cancer. The recent data shows enhanced RET gene expression in patients that have this AR negative neuroendocrine positive phenotype. Drake also highlighted his work in the development of noninvasive ways of detecting RET signaling...
|
- Details
- Kamari Collins, Laila Williams, and Valerie Martinez from San Diego High School join Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to share their visions for their own futures based upon their experiences as a part of the science, Technology, Engineering, and Math (STEM) program at MedTech Academy in San Diego, California. These three dedicated young wo...
|
- Details
- Nick James, a Professor of Clinical Oncology at the Institute of Cancer Research joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) and discusses the developments around the high-volume/low-volume disease in metastatic hormone-sensitive disease from the STAMPEDE trial. They also discuss relapsed disease versus de novo metastatic disease. Biographies: P...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Daniel Spratt joins Charles Ryan to discuss an update of the Shipley data (NEJM 2017) from the RTOG 9601 study. The question discussed is how should we be treating patients who have favorable, lower-volume disease? They also assess the antiandrogen therapy, bicalutamide, that was used in this study versus those available...
|
- Details
- Colin Pritchard joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) where they discuss PARP inhibitor data that came out of the 2019 ESMO meeting including the PROfound study data, rucaparib in TRITON2, and niraparib in the GALAHAD study and focusing on monoallelic versus biallelic BRCA2 alterations. Biographies: Colin C Pritchard, M.D., Ph.D. is the Dire...
|
- Details
- In this discussion with Charles Ryan, MD, Christopher Logothetis discusses his perspective on the direction and growth of the prostate cancer foundation (PCF) and what it has meant to the field of urology. Dr. Logothetis reviews his involvement in the foundation, as well as his thoughts on the developments of treatments and platforms in prostate cancer focusing specifically on differences between...
|
- Details
- Ana Aparicio discusses her work with aggressive variant prostate cancer and her group’s research using immunohistochemistry results and genomic analysis to identify patients with a specific molecular signature. The research concludes that this molecular signature appears to identify the people that benefit from the addition of carboplatin to cabazitaxel chemotherapy. People that have the signature...
|
